Analgesic cross-tolerance between morphine and opioid peptides

The analgesic effect, of intracerebroventricular administration of morphine, ketocyclazocine, [D-ala²]-methionine enkephalinamide (DAM), [D-ala²-D-leu⁵]-enkephalin. (DADLE), leuenkephalin, metenkephalin, and -endorphin on acetic acid-induced abdominal writhing (AAW) was investigated in naive and morphine-tolerant mice. It was found that the relative potencies of a series of opioids are different in naive and morphine-tolerant groups. In naive animals, the order of potency (ED₅₀, nmol) was -endorphin > morphine=DAM > DADLE > ketocyclazocine=leuenkephalin=metenkephalin. The morphine-tolerant animals were cross-tolerant to ketocyclazocine and to all the peptides studied; DAM and -endorphin exhibited the highest degree of tolerance. In morphine-tolerant animals, the order of potency was morphine=DADLE=-endorphin > DAM=ketocyclazocine =metenkephalin > leuenkephalin. The results indicate that endogenous opioid systems may be affected by tolerance development to morphine.     

Species differences in the relative analgesic potencies of some classical opiates and opioid peptides

The analgesic ED₅₀ values of some classical morphine congeners (morphine, methadone, fentanyl, azidomorphine) in the rat and mouse tail-flick tests were found to be similar. However, several synthetic derivatives of the natural enkephalins were more potent in mice than in rats. (These analogs contain d-amino acid in position 2 and d- or l-sulfonic (or phosphonic) acid residue in position 5). -Endorpin, d-Met², Pro⁵-enkephalinamide and two partial agonists showed intermediate interspecies relative potencies. According to the data obtained, similar opiate receptors might mediate the analgesic action of classical opiates in rats and in mice. However, the opiate receptors responsible for the antinociceptive effects of the above mentioned enkephalin analogues must be dissimilar in the two species examined. The results are discussed in terms of the role of - and -receptors in mediation of the analgesic effect induced by different types of opioids.     

Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats

Summary To clarify the effects of withdrawal from chronic morphine treatment on cerebral dopamine (DA) turnover, we have measured the -methyl-p-tyrosine (MT)-induced depletion of DA in five brain areas of male Wistar rats given morphine twice daily for 40 or 60 days. After the last morphine dose (50 or 70 mg/kg) the rats were withdrawn for 1, 2 or 4 days. In order to study the development of tolerance some of the rats were challenged with 10 mg/kg of morphine.Withdrawal of morphine retarded the MT-induced DA depletion in the limbic forebrain and after long enough chronic treatment in the striatum, too. The challenge dose of morphine accelerated the cerebral DA depletion slightly less in rats withdrawn for 1 day from 60-day chronic morphine treatment than in rats treated chronically with saline, but it enhanced the DA depletion more in rats withdrawn from morphine for 2 and 4 days than in chronic saline rats. This enhancement was clearest in rats withdrawn for 4 days from 60-day treatment. Thus withdrawal from morphine seems to sensitize the rats to the DA depletion accelerating effect of morphine.Our results show that repeated administration of morphine creates no marked tolerance to the DA depletion accelerating effect of morphine. In contrast, the dopaminergic neurones of the chronically treated rats seem to depend on continuous morphine administration for their normal functioning. Furthermore, the retarded DA turnover after discontinuation of morphine treatment seems to sensitize the dopaminergic neurones to the DA depletion accelerating effect of morphine. The limbic dopaminergic neurones are more easily affected by both acute and chronic morphine treatment than the striatal ones.     

Incremental repeated acquisition in the rat: acute effects of drugs

Rats lever pressed for food and learned new response sequences on three levers. At the beginning of each daily session, responses on only one of the levers produced food. After meeting criterion on one lever, the task was "incremented" so that sequential responses on two levers were required and so on up to five sequential responses. Each new required response was added in front of the previously performed sequence. Sequences of lever presses required to produce food changed each session. Following establishment of stable acquisition behavior, the acute effects of d-amphetamine (0.30-3.0 mg/kg), diazepam (0.125-4.0 mg/kg), morphine (0.30-10.0 mg/kg), pentobarbital (1.0-17.5 mg/kg), and chlorpromazine (0.10-3.0 mg/kg) were examined. All drugs decreased the number of response sequences completed in a dose-dependent fashion. Response rates generally decreased at or below those doses that caused an increase in errors. For d-amphetamine, the profound disruption of incremental repeated acquisition behavior was primarily due to drug-induced perserverative responding. Pentobarbital and chlorpromazine increased errors both when the sequence was incremented and within the sequence whereas diazepam only increased errors when the sequence was incremented. Morphine generally increased within sequence errors without affecting errors when the sequence was incremented.     

Role of muscarinic cholinergic mechanisms in the substantia nigra pars reticulata in mediating muscular rigidity in rats

Summary Bethanechol chloride (5–25 g), when injected into the substantia nigra pars reticulata (SNR) of rats, produced muscular rigidity in a dose-dependent way, and in addition, catalepsy and ipsilateral posture. The effects of bethanechol in the dose of 25 g were prevented by coadministration of 10 g scopolamine hydrochloride. Injections of 25 g betanechol or 10 g scopolamine into the reticulata only slightly affected the muscular rigiditiy produced by 15 mg/kg i.p. morphine hydrochloride. The results suggest that muscarinic cholinergic mechanisms in the substantia nigra pars reticulata, although effective by themselves, affect by expression of at least one striatal functional alteration, the muscular rigidity, in a less effective way than GABAergic or endogenous opioid mechanisms do.     

吗啡依赖性大鼠模型的建立

目的 :建立吗啡依赖性大鼠实验动物模型。方法 :以剂量递增法形成吗啡依赖模型 ,用纳洛酮催促戒断 ,戒断症状按柳田知司评分法给予评分。结果 :吗啡组戒断症状分值为 19.6 3± 3.4 6 :生理盐水对照组的戒断分值为 6 .2± 1.6 ,两组相比有显著性差异 (p <0 .0 1)。结论 :成功建立了吗啡依赖性大鼠模型     

强制戒毒期海洛因依赖者自测健康的对照分析

目的 探讨强制戒毒期海洛因依赖者自测健康状况。方法 对60名强制戒毒者及60名社区人员采用自测健康评定量表（SRHMS）进行评定。结果 强制戒毒患者的SRHMS总分、生理、心理和社会健康因子分均明显低于社区组,两者之间的差异具有非常显著性意义（P＜0．01）。结论 吸毒严重损害人们的生理、心理及社会健康,提示要采取措施加强对该人群的心理行为干预及监督管理。     

鞘内注射孤啡肽对吗啡耐受形成及吗啡耐受大鼠抗伤害感受作用的影响

目的:观察孤啡肽(OFQ)对大鼠吗啡耐受的形成是否具有延缓作用,以及OFQ与吗啡间是否存在交叉耐受性.方法:本实验运用热辐射甩尾测痛模型,采用鞘内同时注射不同剂量的OFQ与吗啡,观察其对急、慢性吗啡耐受形成的影响;并观察OFQ对吗啡耐受大鼠及吗啡对OFQ耐受大鼠的抗伤害性感受作用.结果:鞘内注射OFQ可延缓慢性吗啡耐受的形成,而对急性吗啡耐受的形成几乎无影响;OFQ与吗啡间无交叉耐受性.结论:OFQ延缓慢性吗啡耐受形成的作用可能与其通过受体后信号转导途径影响G蛋白-AC-cAMP系统有关,也可能与其抑制伏隔核多巴胺的释放有关;OFQ与吗啡耐受形成的机制可能不同,OFQ可能通过其特异性受体发挥脊髓抗伤害性感受作用.     

吗啡依赖和戒断大鼠行为及垂体阿黑皮源基因表达

目的 :结合行为学观察从分子水平上研究吗啡依赖和戒断机理及丁丙诺啡对吗啡戒断的影响。方法 :观察吗啡戒断大鼠的戒断体征及条件性位置偏爱情况 ;利用核酸分子杂交技术研究其垂体阿黑皮源 ( POMC)基因表达的变化。结果 :停用吗啡后 ,大鼠条件性位置偏爱的消失迟于戒断体征 ,吗啡依赖及戒断时垂体 POMC m RNA含量下降。结论 :垂体 POMC基因表达的改变可能是精神依赖产生的生理基础之一     

Early steroid withdrawal in HIV-infected kidney transplant recipients: Utilization and outcomes

Kidney transplant (KT) outcomes for HIV-infected (HIV+) persons are excellent, yet acute rejection (AR) is common and optimal immunosuppressive regimens remain unclear. Early steroid withdrawal (ESW) is associated with AR in other populations, but its utilization and impact are unknown in HIV+ KT. Using SRTR, we identified 1225 HIV+ KT recipients between January 1, 2000, and December 31, 2017, without AR, graft failure, or mortality during KT admission, and compared those with ESW with those with steroid continuation (SC). We quantified associations between ESW and AR using multivariable logistic regression and interval-censored survival analysis, as well as with graft failure and mortality using Cox regression, adjusting for donor, recipient, and immunologic factors. ESW utilization was 20.4%, with more zero HLA mismatch (8% vs 4%), living donors (26% vs 20%), and lymphodepleting induction (64% vs 46%) compared to the SC group. ESW utilization varied widely across 129 centers, with less use at high- versus moderate-volume centers (6% vs 21%, P < .001). AR was more common with ESW by 1 year (18.4% vs 12.3%; aOR: _1.081.61_2.41, P = .04) and over the study period (aHR: _1.021.39_1.90, P = .03), without difference in death-censored graft failure (aHR _0.600.91_1.36, P = .33) or mortality (aHR: _0.751.15_1.77, P = .45). To reduce AR after HIV+ KT, tailoring of ESW utilization is reasonable.